PFM
NBIX icon

Privium Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Privium Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,132
Closed -$1.76M – 182
2022
Q3 		$1.76M Buy
17,132
+3,400
+25% +$345K 0.64% 35
2022
Q2 		$1.34M Hold
13,732
– – 0.44% 38
2022
Q1 		$1.29M Sell
13,732
-48,544
-78% -$4.11M 0.28% 54
2021
Q4 		$5.27M Buy
+62,276
New +$5.73M 1.05% 27

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Privium Fund Management's NBIX Position: Q4 2022 in Review

Privium Fund Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 17,132 shares — an estimated $1.76M sold.

Privium Fund Management first reported a position in NBIX in Q4 2021 and held it in 4 quarters. The position peaked at $5.27M in Q4 2021. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Privium Fund Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Privium Fund Management sold 17,132 Neurocrine Biosciences shares in Q4 2022, an estimated $1.76M.
  • Privium Fund Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 4 quarters.
  • Privium Fund Management's Neurocrine Biosciences position peaked at $5.27M in Q4 2021.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Privium Fund Management's 13F filing for Q4 2022, filed 3 Feb 2023.